financetom
Business
financetom
/
Business
/
Calian Group CEO Kevin Ford to Retire; Patrick Houston Named Successor
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Calian Group CEO Kevin Ford to Retire; Patrick Houston Named Successor
Oct 7, 2025 4:30 AM

07:10 AM EDT, 10/07/2025 (MT Newswires) -- Calian Group ( CLNFF ) said Tuesday that Kevin Ford will retire as chief executive officer after 10 years in the position. He will be succeeded by current chief financial and chief development officer Patrick Houston who assumes the role from Jan. 1.

Houston, who has been at Calian since 2019, said his focus will be on "leading and executing our next-phase multi-year strategic plan, designed to deliver long-term shareholder value and accelerate Calian's evolution as one of Canada's leading industry champions. This includes deepening our presence in the Defence, Space, and Health verticals, capitalizing on a once-in-a-generation investment cycle, and positioning Calian for sustained growth."

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Neuronetics Q3 revenue misses estimates
Neuronetics Q3 revenue misses estimates
Nov 4, 2025
Overview * Neuronetics Q3 2025 revenue rose 101% yr/yr but missed analyst expectations * U.S. Greenbrook clinic revenue grew 25% on an adjusted pro forma basis * CEO Keith J. Sullivan to retire in June 2026, search for successor underway Outlook * Company expects Q4 2025 revenue between $40 mln and $43 mln * Neuronetics ( STIM ) revises 2025...
Sotera Health beats Q3 estimates, raises FY profit guidance
Sotera Health beats Q3 estimates, raises FY profit guidance
Nov 4, 2025
Overview * Sotera Health ( SHC ) Q3 revenue rose 9.1% to $311 mln, beating analyst expectations * Adjusted EPS for Q3 increased to $0.26, surpassing analyst estimates * Adjusted EBITDA for Q3 rose 12.2% to $164 mln, exceeding expectations Outlook * Sotera Health ( SHC ) raises 2025 Adjusted EBITDA growth range to 6.75%-7.75% * Company reaffirms 2025 net...
InspireMD Q3 revenue beats estimates on commercial launch of CGuard Prime
InspireMD Q3 revenue beats estimates on commercial launch of CGuard Prime
Nov 4, 2025
Overview * InspireMD ( NSPR ) Q3 revenue grows 39% yr/yr, beating analyst expectations * Net income for Q3 beats analyst estimates despite larger net loss * Company attributes revenue growth to U.S. launch and international market penetration Outlook * InspireMD ( NSPR ) highlights strong demand for its CGuard Prime globally * Company emphasizes strategic focus on U.S. commercial...
Royalty Pharma Acquires Royalty Interest in Alnylam’s AMVUTTRA for $310 Million from Blackstone Life Sciences
Royalty Pharma Acquires Royalty Interest in Alnylam’s AMVUTTRA for $310 Million from Blackstone Life Sciences
Nov 4, 2025
NEW YORK and CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc ( RPRX ) today announced that it has acquired a royalty interest in Alnylam’s AMVUTTRA from funds managed by Blackstone Life Sciences (“Blackstone”) for $310 million. The royalty interest being sold stems from Blackstone’s 2020 financing collaboration with Alnylam, in which Blackstone invested to support AMVUTTRA’s...
Copyright 2023-2026 - www.financetom.com All Rights Reserved